TOPLINE:

Patients with type 2 diabetes (T2D) who initiated SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection (UTI) had lower risks for mortality, kidney complications, and infection-related outcomes than those who initiated DPP-4 inhibitors.

METHODOLOGY:

UTIs and acute pyelonephritis are common and serious complications in patients with T2D, and the period following these infections is associated with increased risks for systemic complications, renal decline, and cardiovascular events.

Researchers conducted a retrospective cohort study using global health network data from 2016 to 2023 to assess whether initiating SGLT2 inhibitors vs DPP-4 inhibitors within 3 months of a UTI diagnosis is associated with improved long-term outcomes in patients with T2D.

The a

See Full Page